Candel Therapeutics, Inc.

CADL Healthcare Biotechnology

Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.19 0.72 −8.08%
Market cap
$681.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
1/9
Altman Z
−1.20
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
16.09 28.05 13.49 8.25
Net Debt/EBITDA
5.78 9.13 4.66 6.28
Debt/Equity
0.38 0.34 0.91 0.06
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.23) (0.30) (0.21) (0.19)
Book value per Share
1.70 2.21 0.98 1.46
Free Cash Flow
(17.25) (18.71) (10.98) (10.35)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates